- Home
- SLG vs TFX Comparison
SLG vs TFX Comparison
Compare SLG & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLG
- TFX
- Stock Information
- Founded
- SLG 1980
- TFX 1943
- Country
- SLG United States
- TFX United States
- Employees
- SLG N/A
- TFX N/A
- Industry
- SLG Real Estate Investment Trusts
- TFX Medical/Dental Instruments
- Sector
- SLG Real Estate
- TFX Health Care
- Exchange
- SLG Nasdaq
- TFX Nasdaq
- Market Cap
- SLG 4.6B
- TFX 5.1B
- IPO Year
- SLG 1997
- TFX N/A
- Fundamental
- Price
- SLG $57.62
- TFX $113.93
- Analyst Decision
- SLG Hold
- TFX Hold
- Analyst Count
- SLG 16
- TFX 10
- Target Price
- SLG $65.81
- TFX $159.63
- AVG Volume (30 Days)
- SLG 1.1M
- TFX 522.5K
- Earning Date
- SLG 07-16-2025
- TFX 07-31-2025
- Dividend Yield
- SLG 5.42%
- TFX 1.18%
- EPS Growth
- SLG N/A
- TFX N/A
- EPS
- SLG N/A
- TFX 3.20
- Revenue
- SLG $640,547,000.00
- TFX $3,010,144,000.00
- Revenue This Year
- SLG N/A
- TFX $3.50
- Revenue Next Year
- SLG $1.50
- TFX $5.33
- P/E Ratio
- SLG N/A
- TFX $36.07
- Revenue Growth
- SLG N/A
- TFX 0.29
- 52 Week Low
- SLG $45.15
- TFX $108.90
- 52 Week High
- SLG $82.81
- TFX $249.91
- Technical
- Relative Strength Index (RSI)
- SLG 38.70
- TFX 42.85
- Support Level
- SLG $58.50
- TFX $114.98
- Resistance Level
- SLG $60.72
- TFX $118.81
- Average True Range (ATR)
- SLG 1.61
- TFX 2.65
- MACD
- SLG -0.47
- TFX 0.27
- Stochastic Oscillator
- SLG 10.32
- TFX 49.65
About SLG SL Green Realty Corp
SL Green Realty is one of the largest Manhattan property owners and landlords, with interest in around 32 million square feet of wholly owned and joint-venture office space. The company has additional property exposure through its limited portfolio of well-located retail space. It operates as a real estate investment trust.
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.